MC
FOLD

Meteora Capital’s Amicus Therapeutics FOLD Stock Holding History

Meteora Capital’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$821K Sell
56,792
-451,159
-89% -$6.47M 0.06% 150
2025
Q4 		$7.23M Buy
+507,951
New +$4.99M 0.61% 57

Other funds holding FOLD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Meteora Capital's FOLD Position: Q1 2026 in Review

Meteora Capital reduced its Amicus Therapeutics (FOLD) stake by 89% in Q1 2026, selling an estimated $6.47M and leaving 56,792 shares worth $821K. The position accounts for 0.06% of the portfolio, ranked #150.

Meteora Capital first reported a position in FOLD in Q4 2025 and has held it in 2 quarters since. The position peaked at $7.23M in Q4 2025. 298 funds tracked by Wall St. Rank hold FOLD as of Q1 2026.

  • Meteora Capital held 56,792 shares of Amicus Therapeutics worth $821K as of Q1 2026.
  • Meteora Capital sold 451,159 Amicus Therapeutics shares in Q1 2026, an estimated $6.47M.
  • Amicus Therapeutics made up 0.06% of Meteora Capital's portfolio in Q1 2026, its #150 holding.
  • Meteora Capital first reported a position in Amicus Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • Meteora Capital's Amicus Therapeutics position peaked at $7.23M in Q4 2025.
  • 298 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2026.

Based on Meteora Capital's 13F filing for Q1 2026, filed 15 May 2026.